Schedule amended to allow for repeat testing of a participant’s viral load, until this falls below the level of detectability. Trial assessment schedule has been split into two stages, pre and post randomisation, with randomisation becoming a separate visit to ensure all participants have a common baseline. All visits after randomisation are now referred to as post randomisation weeks (PR week), which has been updated throughout. Eligibility assessments including routine blood results and resting 12-lead ECG need to be within 14 days of randomisation. Wording clarified for enrolment exclusion criteria 22. Removed the requirement for participants to attend visits fasted. Changes to the trial assessment schedule only: 1) Screening/baseline visit is now referred to as screening only. 2) Follow up visit at week 08 has been removed. 3) For several visits the volumes and timings of blood samples have been changed. Total blood volume taken across the protocol has increased by 17ml. 4) Visits where quality of life questionnaires are required have changed. Further clarification on the vaccination visits has been included: 1) Specified that the first vaccination (Chad) at PR week 00 must take place within 1 week of randomisation. For participants is Arm A, this visit can be completed over the phone. 2) There is a window of 7 days between the two vaccinations given at PR week 00 and PR08 Day 1. 3) Preliminary results from the BCN01 study are now available. 4) Results from the START study are now available

Continued: Event reporting section has been updated : 1) Only grade 3 adverse events are reportable prior to randomisation. Grade 4 events are reportable throughout the study as SAEs. 2) Pregnancy in a partner is now considered a notable event. 3) Vaccine related events have been added to the notable events and are listed in Appendix IV. 4) For SAEs, participants must be identified by study number, 3 letter code and year of birth only. 5) Clarification that HERVs may be investigated as an exploratory outcome. 6) Re-clarification of the end of the interventional phase of the study and end of study.

Re-clarification of the investigator’s event reporting responsibilities.

Additional QTc information. Change of QTc and bradycardia eligibility criteria. Trial Assessment Schedule only: Additional ECGs at PR10-1 and PR16 included Eligibility has been updated to: 1) Enable sites to use either Hepatitis C RNA or Hepatitis C antigen test to exclude current infection. 2) Enforce use of the CKD-EPI equation to calculate eGFR. Clarification on use of ART prior to enrolment Removed requirement for participants to return empty/part used Raltegravir Removal co-enrolment in UK Register of HIV seroconverters.

Addition of Cohort II – Previously diagnosed participants Additional 18ml blood sample for Merck assay at PR11-1. Change of eGFR eligibility criteria . References to TMG updated to PMG.

Change to coordinating centre address and Clinical Project Manager. Addition of annual follow up phase to visit tables. Added lost to follow up definition during long-term follow-up. Change of long-term follow-up requirements. Added clarification on the notification requirements for Notable Events during long-term follow-up.

Added VIRIAS substudy information including background, rationale, number of participants, eligibility criteria and visit procedures. Addition of VIRIAS substudy references.